Gyre Therapeutics Posts Updated Corporate Presentation (Aug 2026)

What Happened
Gyre Therapeutics, Inc. (GYRE) announced on August 26, 2026 that it made an updated corporate presentation available on its website and filed a Current Report on Form 8-K to disclose the change under Regulation FD. The presentation is furnished as Exhibit 99.1 to the Form 8-K and is dated August 2026.

Key Details

• Filing date: August 26, 2026 (Current Report on Form 8-K).
• Disclosure type: Regulation FD disclosure; corporate presentation furnished as Exhibit 99.1.
• Exhibit included: "Corporate Presentation, dated August 2026" (Exhibit 99.1).
• The Form 8‑K also lists the cover page interactive data file (Inline XBRL) under Item 9.01.

Why It Matters
This 8-K provides investors with the company’s updated investor presentation so stakeholders can review the latest strategic and corporate information directly from Gyre. Because the disclosure was made under Regulation FD and furnished as an exhibit, the update is an official, public source of company information — useful for investors seeking current corporate messaging, pipeline status, milestones, or investor relations materials. Note: the filing does not include earnings, executive changes, or other financial results.